Table of Contents
Introduction: Promising Results in the Recent PROactive Study
Type 2 Diabetes: Disease Background and Prevalence
- Pathophysiology and Risk Factors
- Type 2 Diabetes and Cardiovascular Disease
- Prevalence of Type 2 Diabetes
Overview of Current Drug Therapies
- Sulfonylureas
- Meglitinides
- Alpha-Glucosidase Inhibitors
- Biguanides
- Peroxisome Proliferator-Activated Receptor-Gamma Agonists
- Glucagon-Like Peptide-1 Analogues
- Amylin Analogues
The PROactive Study: Revealing a Potential Breakthrough Treatment for
Cardiovascular Disease in
Type 2 Diabetes
- The Role of PPAR in Cardiovascular Disease
- PROactive Study Design
- PROactive Study Results
- Shortcomings of the PROactive Study
Outlook
| 
View Cart
